Meta-analysis Of GLP-1 Analogue Treatment Type 2 Diabetes In Obese Patients The Efficacy And Safety

Objective:Using meta-analysis methods to analyze the efficacy and safety of GLP-1 analogue therapy in obese patients with T2DM,and make evaluations for them.Methods:With "Liraglutide"、"Exenatide"、"GLP-1"、"obesity"、"diabetes mellitus" as the keywords, search in CNKI、VIP、Wan Fang-database、CMFD、CDFD、pubmed and other database. Retrieval time from January 2005 to March 2015.Screened in the experimental group monotherapy with exenatide or liraglutide, or in combination with other antidiabetic drug therapy, the control group was treated with other antidiabetic drugs (OAD or insulin) in the treatment of randomized controlled trials.Assess the bias and quality of the included studies, and extract information and data from them.Using the Cochrane Collaboration software provides RevMan5.3.5 to analyze the data.Results:Screened 10 RCT studies, Experimental studies have participated in a total complete 727 cases, including 344 cases in the experimental group and control group patients with 383 cases. The results of meta-analysis:HbA1C (MD=-0.54,95%CI:-0.65～-0.43, Z=9.98, p<0.00001); TC[95%CI:-0.52 (-0.85,-0.19), Z=3.06, p=0.002]; TG[95%CI:-0.38 (-0.49,-0.26), Z=6.42, p<0.00001]; BMI[95%CI:-2.36(-3.5,-1.23), Z=4.07, p<0.0001]; the incidence of hypoglycemia[95%CI:-0.07 (-0.16,0.02), Z=1.59, p>0.05], the difference has no statistically significant; gastrointestinal discomfort[95%CI 0.31 (0.14,0.48), Z=3.62, p=0.0003]; Upper gastrointestinal symptoms[95%CI 0.3 (0.12,0.48), Z=3.31, p=0.0009]; Funnel plots are basically symmetrical inverted graphics.Conclusion:Liraglutide or exenatide can control glucose, reduce weight and blood lipids more effectively, Its main side effects are gastrointestinal reactions, especially upper gastrointestinal reactions. Compared with other antidiabetic drugs, It does not increase the risk of hypoglycemia occurred.